Annexon Offers A High-Risk, High-Reward Play On A New Approach To Complement-Mediated Diseases

Annexon (ANNX) stock: high-risk biotech upside from tanruprubart (GBS) & vonaprument (geographic atrophy). Read here for a ...
News-Medical.Net on MSN

Dual-responsive nanodelivery system enhances immunotherapy efficacy in metastatic bladder cancer

Metastatic urothelial carcinoma has a poor prognosis: ~50% of muscle-invasive bladder cancer progresses to metastasis, and ...